Page 12 - Sun Pharma

Sun Pharma net profit declines 27% to Rs 914 cr in December quarter

The company had posted a net profit of Rs 1,241.85 crore for the corresponding period of the previous fiscal

Market Ahead, February 6: All you need to know before the Opening Bell

A total of 135 companies are scheduled to announce their December quarter earnings today including Eicher Motors, Hero MotoCorp, Sun Pharma, and RITES

Market Ahead, February 3: Top factors that could guide markets this week

On the corporate earnings front, Bharti Airtel, Lupin, Sun Pharma, and Mahindra & Mahindra are among the major companies scheduled to declare their October-December results this week

Nifty outlook and top trading ideas by CapitalVia Global Research

Technical Calls by Gaurav Garg, Head of Research at CapitalVia Global Research Limited- Investment Advisor

Pharma shares in focus; Dr Reddy's, Divi's, Granules hit 52-week highs

Lupin, Sun Pharmaceutical, Cadila Healthcare, Aarti Drugs and Aurobindo Pharma were up in the range of 2 per cent to 3 per cent.

Dilip Shanghvi staring at huge loss as Suzlon Energy heads to bankruptcy

Dilip Shanghvi, the Sun Pharma promoter has 23% in renewable power firm that has failed to get debt recast plan

Nifty view & top trading ideas by CapitalVia: Buy Pidilite Ind, Sun Pharma

Technical Calls by Gaurav Garg, Head of Research at CapitalVia Global Research Limited- Investment Advisor

FDA observation, forensic audit by Sebi may keep Sun Pharma under pressure

Halol plant observations add to worries on the extent of upsides from specialty drugs

Sun Pharma declines nearly 3% as Halol facility gets 8 US FDA observations

The company said it was preparing the response to the observations, which will be submitted to the US FDA within 15 business days

Sun Pharma gets partial relief from US court in litigation on generic drugs

Shares of the company on Monday ended 2.18 per cent lower at Rs 440 apiece on the BSE

Specialty drugs, domestic growth prospects positives for Sun Pharma stock

While pricing pressure in the US generics is also stabilising, the specialty products that Sun Pharma has been investing in are seen as a growth driver of its US business

Top biz headlines today: SC Maharashtra order, Zee chairman quits & more

From DGCA directing IndiGo to replace unmodified P&W engines to Karvy denying fund abuse charges, here are the top headlines of the day.

Price-fixing charges: Sun Pharma in talks with US to end anti-trust probe

Prosecutors have been investigating allegations that generic drugmakers conspired to prop up the prices of certain widely used medications for more than five years

Nifty Pharma index hits two-month high; Sun Pharma surges 7%

Among other individual stocks, Lupin, Dr Reddy's Laboratories, Divi's Laboratories and Aurobindo Pharma from the Nifty Pharma index were up 3 per cent each on the NSE.

Here's why Sun Pharma is betting on Japan when peers are losing interest

Recently, Japan's sixth largest generic player Lupin said it felt that the annual price cuts made the market unattractive and it would continue to grow in single digits in value terms

Top 10 biz headlines: Sun Pharma, I-T dept seeks tax mop-up, and more

From PSU general insurance companies to Piramal's financial commitments, here are the top 10 business headlines for the day

Sun Pharmaceutical bullish on Japanese market as peers lose interest

Most Indian players have exited Japan over the past decade. Ranbaxy was one of the early entrants.

Sun Pharma posts Rs 1,433-crore pre-tax profit in Q2, meets estimates

Mumbai, 7 NovemberSun Pharmaceutical Industries' second quarter (Q2; July-September) results are mostly in line with Street expectations, with pre-tax profit of Rs 1,433.4 crore. It was Rs 111.9 crore in the corresponding quarter last year that was impacted by settlements related to anti-trust litigation on its Modafinil drug in the US. Net profit for the quarter is Rs 1,064 crore, with resulting net profit margin at 13.4 per cent. This is against a net loss of Rs 269.6 crore a year before. Adjusted for the exceptional item of Rs 1,214 crore for Q2 last year (Modafinil settlement), net profit growth was 12.6 per cent, the company said. Sales or income from operations was Rs 7,949 crore, up 16 per cent year-on-year (YoY). The India business saw 35 per cent growth YoY to Rs 2,515 crore, while US finished dosage sales remained flat YoY at $339 million. Taro, the US subsidiary, had sales of $161 mn, up one per cent over Q2 last year. Emerging market sales grew only three per cent to ...

Sun Pharma ties up with AstraZeneca to sell novel oncology drugs in China

Sun Pharma has been working out deals through this year to gain foothold in the Chinese market

Sun Pharma climbs over 5% on deal with AstraZeneca, pares gains later

The agreement will be announced later in the day at the China International Import Expo (CIIE) in Shanghai.